Ascendis Pharma A (ASND) Net Margin (2014 - 2026)
Ascendis Pharma A (ASND) posted Net Margin of 256.45% for Q1 2026, up 3236.31% sequentially from 8.18% in Q4 2025, and up 35025.0% YoY from N/an in Q1 2025.
Ascendis Pharma A (ASND) Net Margin (2014 - 2026) Analysis & Trends
Ascendis Pharma A has reported Net Margin for 13 years, with the latest figure at 256.45% in Q1 2026.
- Quarterly Net Margin rose 35025.0% year-over-year to 256.45% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 56.0% (up 4006.0% YoY) and the FY2025 annual result came in at 32.16%, up 6102.0% from the prior year.
- Net Margin grew to 256.45% in Q1 2026 per ASND's latest filing, from 8.18% in the prior quarter.
- Over five years, Net Margin peaked at 1837.99% in Q1 2022 and troughed at 1119.44% in Q3 2022.
- A 5-year average of 164.39% and a median of 136.65% in 2024 frame the typical range for Net Margin.
- The sharpest annual moves came in 2022 and 2023: Net Margin tumbled 1181574 bps in 2022, then jumped 145716 bps in 2023.
- Over 5 years, Net Margin stood at 905.96% in 2022, then jumped by 97 bps to 29.19% in 2023, then surged by 57 bps to 12.41% in 2024, then surged by 34 bps to 8.18% in 2025, then surged by 3236 bps to 256.45% in 2026.
- According to Business Quant data, Net Margin over the past three periods registered 256.45%, 8.18%, and 29.29% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 30.33% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.90% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 30.98% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 12.74% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -3.12% |
| 10 | Ascendis Pharma A | 15.40 Bn | 14.73 Bn | 268.20 Mn | 256.45% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 256.45% |
| Dec 31, 2025 | -8.18% |
| Sep 30, 2025 | -29.29% |
| Jun 30, 2025 | 25.47% |
| Mar 31, 2025 | -93.81% |
| Dec 31, 2024 | -12.41% |
| Sep 30, 2024 | 171.52% |
| Jun 30, 2024 | 303.85% |
| Mar 31, 2024 | 136.65% |
| Dec 31, 2023 | -29.19% |
| Sep 30, 2023 | 337.73% |
| Jun 30, 2023 | 258.37% |
| Mar 31, 2023 | 332.55% |
| Dec 31, 2022 | -905.96% |
| Sep 30, 2022 | -1,119.44% |
| Jun 30, 2022 | 1,332.40% |
| Mar 31, 2022 | 1,837.99% |
| Dec 31, 2021 | -123.14% |
| Sep 30, 2021 | 7,219.05% |
| Jun 30, 2021 | 13,148.14% |